A detailed history of Wells Fargo & Company transactions in Regulus Therapeutics Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 26,585 shares of RGLS stock, worth $40,675. This represents 0.0% of its overall portfolio holdings.

Number of Shares
26,585
Previous 25,848 2.85%
Holding current value
$40,675
Previous $46,000 10.87%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$1.46 - $1.9 $1,076 - $1,400
737 Added 2.85%
26,585 $41,000
Q2 2024

Aug 13, 2024

BUY
$1.79 - $2.8 $46,013 - $71,976
25,706 Added 18102.82%
25,848 $46,000
Q1 2024

May 10, 2024

BUY
$1.13 - $2.88 $2 - $5
2 Added 1.43%
142 $0
Q4 2023

Feb 09, 2024

BUY
$1.21 - $1.44 $14 - $17
12 Added 9.38%
140 $0
Q3 2023

Nov 13, 2023

BUY
$1.27 - $1.76 $1 - $1
1 Added 0.79%
128 $0
Q2 2023

Aug 15, 2023

BUY
$0.87 - $1.75 $18 - $36
21 Added 19.81%
127 $0
Q1 2023

May 12, 2023

BUY
$0.79 - $1.61 $11 - $22
14 Added 15.22%
106 $0
Q4 2022

Feb 13, 2023

BUY
$1.17 - $1.85 $2 - $3
2 Added 2.22%
92 $0
Q3 2022

Nov 14, 2022

SELL
$1.35 - $2.39 $847 - $1,500
-628 Reduced 87.47%
90 $0
Q2 2022

Aug 12, 2022

BUY
$1.6 - $3.4 $1,148 - $2,441
718 New
718 $1,000

Others Institutions Holding RGLS

About Regulus Therapeutics Inc.


  • Ticker RGLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 14,634,400
  • Market Cap $22.4M
  • Description
  • Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-thre...
More about RGLS
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.